000149055 001__ 149055
000149055 005__ 20260316125347.0
000149055 0247_ $$2doi$$a10.1016/j.eprac.2023.10.131
000149055 0248_ $$2sideral$$a142174
000149055 037__ $$aART-2023-142174
000149055 041__ $$aeng
000149055 100__ $$aSánchez Malo, María José
000149055 245__ $$aImportance of Growth Factors and Bone Maturation Ratio in the Response to Growth Hormone Therapy
000149055 260__ $$c2023
000149055 5203_ $$aObjective
The aim was to identify the influence of insulin-like growth factor I (IGF-1), IGF-binding protein-3 (IGFBP-3), and bone age (BA)/chronological age (CA) ratio on the response to GH therapy after 1 and 2 years of treatment and upon reaching final height.
Methods
Longitudinal, retrospective, observational study of 139 patients treated for idiopathic growth hormone deficiency. Variables examined during follow-up: (1) genetic background; (2) perinatal history; (3) anthropometry; (4) height velocity, BA, BA/CA and height prognosis; (5) analytical results (IGF-1, IGFBP-3). Final response variables: adult height (AH), AH with respect to target height, AH with respect to initial height prognosis, AH with respect to height at the start of treatment, and AH with respect to height at onset of puberty.
Results
Lower pretreatment IGF-1 levels and a greater increase in IGF-1 at the end of treatment imply a better response (r = −0.405, P = .007 and r = 0.274, P = .014, respectively), as does a greater increase in IGFBP-3 after 2 years of treatment and at the end of treatment (r = 0.207, P = .035 and r = 0.259, P = .020, respectively). A lower BA/CA ratio pretreatment and at the onset of puberty results in a better response (r = −0.502, P = .000 and r = −0.548, P = .000, respectively), as does a lower increase in BA and BA/CA ratio after the 1 and 2 years of treatment (r = −0.337, P = .000 and r = −0.332, P = .000, respectively).
Conclusion
Low pretreatment IGF-1, a greater BA delay with respect to CA pretreatment and at the onset of puberty, a greater increase in IGFBP-3 after 2 years of treatment, and a lower increase in BA and BA/CA ratio after 1 and 2 years of treatment imply a better long-term response.
000149055 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000149055 590__ $$a3.7$$b2023
000149055 591__ $$aENDOCRINOLOGY & METABOLISM$$b62 / 186 = 0.333$$c2023$$dQ2$$eT2
000149055 592__ $$a1.208$$b2023
000149055 593__ $$aEndocrinology$$c2023$$dQ1
000149055 593__ $$aMedicine (miscellaneous)$$c2023$$dQ1
000149055 593__ $$aEndocrinology, Diabetes and Metabolism$$c2023$$dQ1
000149055 594__ $$a7.6$$b2023
000149055 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000149055 700__ $$aHidalgo Sanz, Juan
000149055 700__ $$aFerrer Lozano, Marta
000149055 700__ $$0(orcid)0000-0003-2832-2266$$aLabarta Aizpún, Jose Ignacio$$uUniversidad de Zaragoza
000149055 700__ $$0(orcid)0000-0002-2865-5813$$ade Arriba Muñoz, Antonio$$uUniversidad de Zaragoza
000149055 7102_ $$11011$$2670$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Pediatría
000149055 773__ $$g30, 1 (2023), 57-63$$pENDOCRINE PRACTICE$$tENDOCRINE PRACTICE$$x1530-891X
000149055 8564_ $$s881715$$uhttps://zaguan.unizar.es/record/149055/files/texto_completo.pdf$$yVersión publicada
000149055 8564_ $$s2619267$$uhttps://zaguan.unizar.es/record/149055/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000149055 909CO $$ooai:zaguan.unizar.es:149055$$particulos$$pdriver
000149055 951__ $$a2026-03-16-08:29:35
000149055 980__ $$aARTICLE